Raymond James analyst Steven Seedhouse maintains $Gilead Sciences (GILD.US)$ with a buy rating, and adjusts the target price from $93 to $103.
According to TipRanks data, the analyst has a success rate of 41.4% and a total average return of 10.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Gilead Sciences (GILD.US)$'s main analysts recently are as follows:
Gilead's recent financial results exceeded sales expectations, bolstered by robust performance within its HIV product lineup and higher than anticipated revenues from Veklury. The company's HIV segment experienced a solid quarter marked by ongoing volume increases and a positive product mix.
The company's third-quarter performance surpassed expectations, bolstered not only by Veklury but by Biktarvy as well.
The sentiment is that significant changes are underway for the company, as it shifts away from past business development decisions and refocuses on its core strength in antiviral innovation. The introduction of lenacapavir is anticipated to have a dual role, acting as a next-generation foundation for HIV treatment and potentially broadening the scope of PrEP to a wider audience. There's a belief that the PrEP market holds potential for expansion beyond the traditional high-risk demographics. In the oncology space, there's notable progress, with TRODELVY experiencing double-digit growth and a promising partnership that could lead to a leading CAR-T therapy for multiple myeloma.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
